ANR Anatara Lifesciences Limited
—Mkt Cap: —P/E: —1d ago
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include irritable bowel syndrome; and De…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value1.64M USD
Revenue (TTM)220.04K USD
Gross Profit26.19K USD
Net Income (TTM)-644.94K USD
Revenue/Share0.0010 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000ANR0
Valuation
P/E (Trailing)—
P/E (Forward)0.45
PEG—
EV/EBITDA-2.54
EV/Revenue7.45
P/S8.94
P/B4.50
EPS (TTM)0.00
EPS (Forward)0.02
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin11.90%
Oper. Margin-299.81%
EBITDA Margin-293.66%
Profit Margin-293.10%
ROE-149.62%
ROA-59.37%
Growth
Revenue Growth-68.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-234.44K USD
CapEx (TTM)—
FCF Margin6.18%
FCF Yield—
Net Debt-325.44K USD
Net Debt/EBITDA0.50
Balance Sheet
Debt/Equity—
Current Ratio7.58
Quick Ratio7.44
Book Value/Sh0.0020 AUD
Cash/Share0.0010 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.316.31M
Float211.13M
Insiders33.43%
Institutions10.44%
Technical
SMA 500.0091 AUD
SMA 2000.0100 AUD
Beta0.65
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)39.60K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—